Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

Lung Cancer

Volumn 52, Issue 2, 2006, Pages 189-197

  Powell, Alex ^a   Creaney, Jenette ^a   Broomfield, Steven ^a   Van Bruggen, Ivonne ^a   Robinson, Bruce ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Delayed type hypersensitivity; Granulocyte macrophage colony stimulating factor; MM; Tumor lysate; Vaccine; Western blot

Indexed keywords

CANCER VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL LYSATE; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPOTHYROIDISM; INJECTION SITE PAIN; LETHARGY; MALE; MALIGNANT MESOTHELIOMA; MYALGIA; PERICARDITIS; PERITONITIS; PRIORITY JOURNAL; RIGOR; SKIN TEST; SURVIVAL RATE; SURVIVAL TIME; SYNOVITIS; THORAX PAIN; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION REACTION; VASCULITIS; VITILIGO; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CANCER VACCINES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 33645993930     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.01.007     Document Type: Article

References (26)

1. Devita Jr. V.T., Hellman S., and Rosenberg. Cancer: principles and practice of oncology. 7th ed. (2005), Lippincott Co., Philadelphia, PA
2. Hillerdal G., et al. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77 (1983) 321
3. Ruffie P., Feld R., Minkin S., et al. Diffuse malignant mesothelioma pf the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7 (1989) 1157
4. Britton M. The epidemiology of mesothelioma. Semin Oncol 21 1 (2002) 18-25
5. Musk A.W., and de Klerk N.H. Epidemiology of mesothelioma in Western Australia. Lung Cancer 455 (2004) S21-S23
6. Vogelzang N.J., Rusthoven J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
7. Robinson B.W.S., Robinson C., and Lake R. Localised spontaneous mesothelioma regression in mesothelioma-probable immunological mechanism. Lung Cancer 32 2 (2001) 197-201
8. Mukherjee S., Nelson D.J., Loh S., et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 8 (2001) 580-588
9. Caminschi I., Venetsanakos E., Leong C.C., et al. Interleukin-12 induces an effective anti-tumour response in malignant mesothelioma. Am J Resp Cell Mol Biol 19 5 (1998) 738-746
10. Astouli P., Picat-Joossen D., Viallat J.R., et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant mesothelioma: a phase II study. Cancer 83 10 (1998) 2099-2104
11. Upham J.W., Musk A.W., Van Hazel G., et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med 23 6 (1993) 683-687
12. Davidson J.A., Musk A.W., Wood B.R., et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion on mesothelioma. J Immunother 21 5 (1998) 389-398
13. Dranoff G., Jaffe E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci 90 (1993) 3539-3543
14. Kwak L.W., Young H.A., Pennington R.W., et al. Vaccination with syngeneic, lymphoma derived immunoglobulin idiotype combined with granulocyte macrophage colony-stimulating factor primes mice for a protective T cell response. Proc Natl Acad Sci 93 (1996) 10972-10977
15. Leong S.P., Enders-Zohr P., Zhou Y.M., et al. Recombinant human granulocyte macrophage-colony stimulating factor and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22 2 (1999) 166-174
16. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nat Med 4 (1998) 328-332
17. Robinson C., Callow M., Stevenson S., et al. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. J Respir Cell Mol Biol 22 5 (2000) 550-556
18. Leong S.P., Enders-Zohr P., Zhou Y.M., et al. Recombinant human granulocyte macrophage-colony stimulating factor and autologous melanoma vaccine mediate tumour regression in patients with metastatic melanoma. J Immunother 22 2 (1999) 166-174
19. Jones R.C., Kelly M., Gupta R.K., et al. Immune response to polyvalent melanoma cell vaccine in AJCC Stage III melanoma: an immunologic survival model. Ann Surg Oncol 3 5 (1996) 437-445
20. Alberts A.S., Falkson G., Goedhals L., et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6 3 (1988) 527-535
21. Nowak A.K., Robinson B.W., and Lake R. Gemcitabine exerts a selective effect on the humoral immune response: implications for chemo-immunotherapy. Cancer Res 62 (2002) 2353-2358
22. Nowak A.K., Robinson B.W., and Lake R. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumours. Can Res 63 (2003) 4490-4496
23. O'Brien M.E., Saini A., Smith I.E., et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 83 7 (2000) 853-857
24. Webster I., Cochrane J.W., Burkardt K.R., et al. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S Afr Med J 61 8 (1982) 277-278
25. Rusch V.W. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 103 (1993) 382S-384S
26. Sugarbaker D.J., Garcia J.P., Richards W.G., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 3 (1996) 288-294 [discussion 294-296]